Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer, N. Cook, T. Arkenau, J. Melear, C. Redfern, A. I. Spira, K. Chung, T. Haddad, S. S. Ramalingam, R. Wesolowski, E. Dean, T. Goddemeier, M. Falk, G. Shapiro

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii519
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this